Navigation Links
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
Date:8/14/2014

the comparable period in 2013. The decrease of $1.2 million is due to due changes in the Company's closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter.

Preferred stock dividends were $3.0 million for the six months ended June 30, 2014, compared to $5.9 million for the comparable period in 2013. The decrease of $2.9 million is due to due changes in the Company's closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter.

About RXi Pharmaceuticals CorporationRXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the Company's Scientific Advisory Board, RXi's first RNAi product candidate, RXI-109, entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce dermal scarring (fibrosis).  RXI-109 is also being evaluated in pre-clinical studies for retinal scarring.  RXI-109 targets connective tissue growth factor (CTGF), a key player in development of dermal scarring, retinal scarring and fibrosis. RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and ant
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 , ... ... and managed with the use of special anti-vascular endothelial growth factor agents given ... more patients, currently does not have a scientific protocol for the many millions ...
(Date:9/2/2015)... Research and ... addition of Jain PharmaBiotech,s new report ... to their offering. The scope ... in situ hybridization (FISH), comparative genomic hybridization ... application of nanobiotechnology, microarrays, real-time polymerase chain ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... SOUTH SAN FRANCISCO, Calif. , Sept. 2, 2015 ... announced that Bonnie H. Anderson , president and ... Global Healthcare Conference on Wednesday, September 16, 2015 at ... . The live audio webcast ... http://investor.veracyte.com . The webcast will be available shortly ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2
... - MC Strategies, New ... of Radiologic Technologists, Managers , ... http://www.mosbysimagingsuite.com ), the first fully integrated, online,solution developed ... challenges of radiologic technologists and managers. , ...
... RainDance Technologies, Inc., a privately held provider ... disease research, today announced it will be shipping ... and reviewed the company,s opportunities for growth at ... initial application of the company,s RainStorm(TM) microdroplet-based technology ...
... Alvaro Fernandez Previews Upcoming SharpBrains Market Report at IHRSA 2009 Convention. ... ... Alvaro Fernandez, CEO of SharpBrains and member of the World Economic ... at the IHRSA (International Health, Racquet and Sportsclub Association) Annual Convention ...
Cached Biology Technology:New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 2New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 3New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 4RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference 2RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference 3New Brain Fitness Survey Reinforces Importance of Brain Awareness Week 2New Brain Fitness Survey Reinforces Importance of Brain Awareness Week 3New Brain Fitness Survey Reinforces Importance of Brain Awareness Week 4
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/10/2015)... 2015 The latest 364 page report ... of the global border security market . Visiongain ... in 2015. Now: Border security is hard to ... the business critical issue you need to know about - ... objective analysis of how this will impact your company and ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... from the NIOZ Royal Netherlands Institute for Sea Research ... for tropical central Africa over the past 25,000 years. ... from the University of Bremen, The scientists developed an ... temperatures based on the molecular fossils of soil bacteria. ...
... by the body. It cannot regenerate itself, because it is ... the time the tooth appears in the mouth. The enamel ... and decay. For this reason, it is exciting to consider ... using culturing and transplantation techniques. In the emergent field of ...
... has emerged as a promising alternative for ... and tissues, circumventing the complications associated with ... or regenerate damaged tissue by using engineered ... regeneration and eventually integrate into the host ...
Cached Biology News:Microfossils unravel climate history of tropical Africa 2Scientists re-grow dental enamel from cultured cells 2
... The binding specificity and signaling of the ... to be modified by alternative splicing--which has ... SpliceArrays you can perform a classical expression ... the different alternatively spliced forms of the ...
... important role in the regulation of signaling ... Splice variants have been reported that affect ... apoptotic pathways. With Apoptosis and Cell Death ... expression profiling and at the same time ...
... The RapidTrace SPE Workstation is a ... phase extraction platform. Utilizing 1ml or 3ml ... process up to 100 samples in less ... be loaded with 10 cartridges, and up ...
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
Biology Products: